Retrieve available abstracts of 41 articles: HTML format
Single Articles
May 2025
HASSAN H, Allen I, Rahman T, Allen S, et al Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2
pathogenic variant carriers with personal history of breast cancer: a
retrospective cohort study using linked electronic health records.
Lancet Oncol. 2025 May 7:S1470-2045(25)00156. PubMedAbstract available
BLONDEAUX E, Sonnenblick A, Agostinetto E, Bas R, et al Association between risk-reducing surgeries and survival in young BRCA carriers
with breast cancer: an international cohort study.
Lancet Oncol. 2025 May 7:S1470-2045(25)00152. PubMedAbstract available
ESCRIVA-DE-ROMANI S, Cejalvo JM, Alba E, Friedmann J, et al Zanidatamab plus palbociclib and fulvestrant in previously treated patients with
hormone receptor-positive, HER2-positive metastatic breast cancer: primary
results from a two-part, multicentre, single-arm, phase 2a study.
Lancet Oncol. 2025 May 5:S1470-2045(25)00140. PubMedAbstract available
JENSEN MB, Torpe E, Teunissen Z, Taarnhoj G, et al Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with
early breast cancer: a nationwide, prospective cohort study by the Danish Breast
Cancer Group.
Lancet Oncol. 2025;26:654-662. PubMedAbstract available
KUEMMEL S, Graeser M, Schmid P, Reinisch M, et al Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and
pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm,
phase 2 trial.
Lancet Oncol. 2025;26:629-640. PubMedAbstract available
GRUBER K Monstrosity of Tiny Tumours: an artist's journey through breast cancer.
Lancet Oncol. 2025;26:558. PubMed
March 2025
DEVI S Projected global rise in breast cancer incidence and mortality by 2050.
Lancet Oncol. 2025 Mar 6:S1470-2045(25)00136. PubMed
ZDENKOWSKI N, Kuper-Hommel MJJ, Niman SM, Francis PA, et al Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early
triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative,
open-label, randomised, phase 2 trial.
Lancet Oncol. 2025;26:367-377. PubMedAbstract available
MAGSANOC-ALIKPALA MJK, Ylanan AMD, Rivera-Montales C, Magsanoc JM, et al Breast cancer survivor-led patient advocacy: the ICanServe experience from the
Philippines.
Lancet Oncol. 2025;26:287-289. PubMed
GONCALVES A, de Nonneville A Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast
cancer.
Lancet Oncol. 2025;26:273-274. PubMed
February 2025
AHN HK, Kim JY, Lee KH, Kim GM, et al Palbociclib plus endocrine therapy versus capecitabine in premenopausal women
with hormone receptor-positive, HER2-negative metastatic breast cancer
(Young-PEARL): overall survival analysis of a randomised, open-label, phase 2
study.
Lancet Oncol. 2025 Feb 17:S1470-2045(25)00006. PubMedAbstract available
MUNZONE E, Valenza C Tailoring the treatment of premenopausal patients with breast cancer.
Lancet Oncol. 2025 Feb 17:S1470-2045(25)00060. PubMed
BONNEFOI H, Lerebours F, Pulido M, Arnedos M, et al Darolutamide or capecitabine in triple-negative, androgen receptor-positive,
advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative,
randomised, phase 2 trial.
Lancet Oncol. 2025 Feb 17:S1470-2045(24)00737. PubMedAbstract available
SRIDHAR N, Ueno NT Navigating the androgen receptor landscape in triple-negative breast cancer.
Lancet Oncol. 2025 Feb 17:S1470-2045(25)00029. PubMed
VENKATESAN P Largest trial of AI in breast cancer screening launched.
Lancet Oncol. 2025 Feb 13:S1470-2045(25)00080. PubMed
CASASSUS B Law to extend free medical treatment for breast cancer in France.
Lancet Oncol. 2025 Feb 6:S1470-2045(25)00069. PubMed
January 2025
LI L FNAB samples with the STRAT4 assay for breast cancer diagnosis.
Lancet Oncol. 2025;26:e9. PubMed
NG DL, Van Loon K, Weidler J, Bates M, et al FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply.
Lancet Oncol. 2025;26:e10. PubMed
December 2024
GRUBER K Pesticide exposure and increased risk of breast cancer for women in rural Brazil.
Lancet Oncol. 2024 Dec 19:S1470-2045(24)00726. PubMed
HENRY NL Optimising therapy and avoiding overtreatment in breast cancer.
Lancet Oncol. 2024 Dec 11:S1470-2045(24)00707. PubMed
MEATTINI I, De Santis MC, Visani L, Scorsetti M, et al Single-modality endocrine therapy versus radiotherapy after breast-conserving
surgery in women aged 70 years and older with luminal A-like early breast cancer
(EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised
trial.
Lancet Oncol. 2024 Dec 11:S1470-2045(24)00661. PubMedAbstract available
RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced
breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2,
multicentre, open-label, non-comparative study.
Lancet Oncol. 2024;25:e629-e638. PubMedAbstract available
November 2024
CHEN XC, Jiao DC, Qiao JH, Wang CZ, et al De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab
versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with
HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3
trial.
Lancet Oncol. 2024 Nov 26:S1470-2045(24)00581. PubMedAbstract available
LUND M, Corn G, Jensen MB, Petersen T, et al Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with
early breast cancer in Denmark: a cohort study of real-world data.
Lancet Oncol. 2024;25:1496-1506. PubMedAbstract available
OLIVEIRA M, Pominchuk D, Nowecki Z, Hamilton E, et al Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal
women with oestrogen receptor-positive, HER2-negative advanced breast cancer
(SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
Lancet Oncol. 2024;25:1424-1439. PubMedAbstract available
October 2024
NG DL, Vuhahula E, Kimambo AH, Ndayisaba MC, et al Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a
resource-constrained setting: a prospective diagnostic accuracy study.
Lancet Oncol. 2024 Oct 3:S1470-2045(24)00456. PubMedAbstract available
September 2024
OLIVEIRA M, Rugo HS, Howell SJ, Dalenc F, et al Capivasertib and fulvestrant for patients with hormone receptor-positive,
HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes
from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2024;25:1231-1244. PubMedAbstract available
KOLBERG HC, Kolberg-Liedtke C Who does not benefit from whole-breast radiotherapy and how to find them?
Lancet Oncol. 2024;25:1110-1111. PubMed
DE BONIFACE J, Appelgren M, Szulkin R, Alkner S, et al Completion axillary lymph node dissection for the identification of pN2-3 status
as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of
the randomised, phase 3 SENOMAC trial.
Lancet Oncol. 2024;25:1222-1230. PubMedAbstract available
August 2024
GOURD E Disappointment facing patients with breast cancer as trastuzumab deruxtecan too
expensive for NHS.
Lancet Oncol. 2024 Aug 8:S1470-2045(24)00446. PubMed
WILLIAMS LJ, Kunkler IH, Taylor KJ, Dunlop J, et al Postoperative radiotherapy in women with early operable breast cancer (Scottish
Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3
trial.
Lancet Oncol. 2024 Aug 7:S1470-2045(24)00347. PubMedAbstract available
BARRIO AV Time to abandon axillary lymph node dissection in early-stage breast cancer.
Lancet Oncol. 2024 Aug 6:S1470-2045(24)00385. PubMed
July 2024
OFUYA M Overcoming barriers to early breast cancer presentation in Nigeria.
Lancet Oncol. 2024;25:840. PubMed
GOURD E Olufunmilayo Olopade-preventive oncologist using genetics to fight breast cancer
in high-risk populations.
Lancet Oncol. 2024;25:839. PubMed
PELLERIN R New Canadian draft breast screening guidelines issued.
Lancet Oncol. 2024;25:836. PubMed
May 2024
FEHM T, Cottone F, Dunton K, Andre F, et al Trastuzumab deruxtecan versus treatment of physician's choice in patients with
HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported
outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol. 2024;25:614-625. PubMedAbstract available
April 2024
VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III
HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104. PubMedAbstract available
BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive
breast cancer.
Lancet Oncol. 2024;25:e139-e151. PubMedAbstract available
LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al Gedatolisib in combination with palbociclib and endocrine therapy in women with
hormone receptor-positive, HER2-negative advanced breast cancer: results from the
dose expansion groups of an open-label, phase 1b study.
Lancet Oncol. 2024;25:474-487. PubMedAbstract available
March 2024
TOI M, Kinoshita T, Benson JR, Jatoi I, et al Non-surgical ablation for breast cancer: an emerging therapeutic option.
Lancet Oncol. 2024;25:e114-e125. PubMedAbstract available
October 2023
MUTTER RW, Giri S, Fruth BF, Remmes NB, et al Conventional versus hypofractionated postmastectomy proton radiotherapy in the
USA (MC1631): a randomised phase 2 trial.
Lancet Oncol. 2023;24:1083-1093. PubMedAbstract available